Business
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually.
About this update from Halberd Corp.
[{"type":"text","content":"Jackson Center, Pennsylvania--(Newsfile Corp. - February 22, 2022) - Halberd Corporation (OTC Pink: HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to an entirely new way of treating PTSD, Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE), Alzheimer's Disease, Parkinson's Disease, Epilepsy and other neurodegenerative diseases. Halberd's unique approach allows for precise control of the level of inflammatory cytokines, proteins, and amino acids in CSF to produce and maintain healthy brain function.Top Ten Neurological PathogensProof of Eradication from CSF ResultsAssociated Antigens(Top 10)PTSD/CTENeurodegenerative Diseases*Phosphorylated TauCompletedCompletedIL-6CompletedCompletedTNF-αCompletedCompletedIL-1N/ACompletedIL-12N/ACompletedIL-2N/ACompletedBeta AmyloidN/ACompletedIL-4N/ACompletedTauCompletedCompletedGlutamateCompletedCompleted N/A - indicates antigen is not associated with listed condition.* -- Includes Alzheimer's, Parkinson's, Epilepsy & Lou Gehrig's DiseasesDr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, \"Glutamate is associated with a number of neurodegenerative conditions. Being able to precisely control glutamate levels in a patient would provide a powerful tool in the treatment of these conditions.\"Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Science Department at Youngstown State University, who oversees Halberd's patented laser and radio frequency test program, commented, \"It is exciting to see a single approach demonstrating such overwhelming success given the large range of antigen sizes addressed We have experienced complete elimination of all 10 neurodegenerative disease-associated antigens in the lab, and we find elimination occurs in especially short laser exposure times. It is difficult to see how this method could be overlooked as an improved way to treat neurodegenerative diseases.\"William A. Hartman, Halberd's Chairman, President & CEO added, \"This breakthrough will give hope to the 36 millio...